Inogen (INGN) Net Equity Issued and Repurchased (2025)

Inogen's (INGN) quarterly Net Equity Issued and Repurchased came in at $27.2 million in Q1 2025.

Inogen (INGN) Net Equity Issued and Repurchased (2025) Analysis & Trends

Inogen (INGN) has 1 years of Net Equity Issued and Repurchased data on file, last reported at $27.2 million in Q1 2025.

On a quarterly basis, Net Equity Issued and Repurchased changed N/A year-over-year to $27.2 million in Q1 2025; TTM through Dec 2025 was $27.2 million, a N/A change from a year earlier, with the FY2025 full-year figure at $27.2 million, changed N/A from the prior year.
Net Equity Issued and Repurchased for Q1 2025 stood at $27.2 million.
Over the last five years, Net Equity Issued and Repurchased for INGN reached as high as $27.2 million in Q1 2025 and fell as low as $27.2 million in Q1 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Equity Issued and Repurchased (Qtr)
1	Abbott Laboratories	201.40 Bn	194.75 Bn	6.27 Bn	-
2	Stryker	122.29 Bn	119.41 Bn	3.81 Bn	-
3	Medtronic	105.01 Bn	96.40 Bn	6.41 Bn	97.00 Mn
4	Boston Scientific	64.81 Bn	63.59 Bn	3.61 Bn	-
5	Edwards Lifesciences	55.28 Bn	51.60 Bn	1.29 Bn	-
6	Dexcom	29.06 Bn	27.94 Bn	750.30 Mn	12.70 Mn
7	Koninklijke Philips	29.02 Bn	25.93 Bn	2.07 Bn	-
8	GE HealthCare Technologies	28.27 Bn	26.20 Bn	1.98 Bn	-
9	Smith & Nephew	25.80 Bn	25.22 Bn	-	-
10	Inogen	172.68 Mn	62.51 Mn	37.86 Mn	-

Download Data

Date	Value
Mar 31, 2025	27.21 Mn
Mar 31, 2025	27.21 Mn